OPC-2071
- Generic Name
- OPC-2071
Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type
Phase 2
Completed
- Conditions
- Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
- Interventions
- Drug: placebo
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 87
- Registration Number
- NCT05923892
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2021-06-15
- Target Recruit Count
- 3
- Registration Number
- NCT03850509
- Locations
- 🇺🇸
United States, California, San Carlos, California, United States
🇺🇸United States, South Carolina, Rock Hill, South Carolina, United States
🇺🇸United States, Georgia, Doraville, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath